期刊文献+

综合性医院门诊患者口服质子泵抑制剂的回顾性处方点评 被引量:17

Retrospective comments on Prescriptions of Oral Proton Pump Inhibitors for Outpatients in A General Hospital
下载PDF
导出
摘要 目的了解口服质子泵抑制剂(PP1)的临床应用模式,并促进其合理用药。方法利用医院信息系统药房管理子系统,对2007年1月10日~1月21日期间某综合性三甲医院门诊患者含口服PPI的处方进行回顾性点评。合理性标准为药品说明书、国内外循证医学研究结果、PPI临床应用指导原则。结果该院的口服PPI应用总体较为合理,但临床诊断与适应证的吻合程度存在一定欠缺。部分处方的临床诊断不能反映就诊科室的专科特点。一些处方在用法用量和合并用药方面的合理性值得商榷。结论临床医生应对药品说明书有更多的了解,适应证以外用法时应告知患者。药师在加强处方审核力度的同时,也应注意灵活性,应注意学习治疗学的最新进展。 OBJECTIVE To know the pattern of clinical use of oral proton pump inhibitors (PPIs) and enhance their rational drug use. METHODS Retrospective comments on prescriptions containing oral PPIs in a 3-A-grade general hospital between Jan 10, 2007 and Jan 21,2007 were performed using a pharmacy administration software. The criteria for judging rationality included package insert of product, results of related evidence-based medicine studies, standard therapeutic guidance for PPIs use enacted by The National Institute for Clinical Excellence, UK. RESULTS In generally,the clinical use of oral PPIs are reasonable. However,there are certain discrepancies between diagnose and indications. Diagnoses in some prescriptions could not reflect the specialty of clinical departments. Rationality in dosage, administration and combined medication of PPIs in some prescriptions is worth discussing. CONCLUSION Doctors should know more about the package insert of the product and should let their patients know when PPI could be used beyond approved indications. Pharmacists should pay attention to the flexibility principle while strengthening prescription cheek and should learn the latest developments in clinical therapeutics.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2008年第4期353-357,共5页 Chinese Journal of Modern Applied Pharmacy
基金 浙江省教育厅科技计划(编号:20061449) 浙江省康恩贝医院管理研究项目(编号:2007AZHA-KEB312)
关键词 质子泵抑制剂 药物利用 合理用药 处方点评 proton pump inhibitors drug utilization rational drug use comments on prescription
  • 相关文献

参考文献3

二级参考文献35

  • 1Laheij R J, Van Rossum LG, Jansen JB, Verheugt FW.Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther, 2003,18:109-115.
  • 2Graham DY, Agrawal NM, Campbell DR, Haber MM,Collis C, Lukasik NL, Huang B; NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multiceuter,active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med, 2002, 162:169-175.
  • 3Chryssostalis A, Marck G, Sibilia J, Chaussade S.Prevention of gastroduodenal complications in patients taking low-dose aspirin. Gastroenterol Clin Biol, 2004, 28 Spec No 3: C84-C89.
  • 4Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM,van Rensburg CJ, Swannell AJ, Hawkey CJ. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med, 1998, 338: 719-726.
  • 5Hawkey CJ, Karraseh JA, Szczepanski L, Walker DG,Barkun A, Swannell AJ, Yeomans ND. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management(OMNIUM) Study Group. N Engl J Med, 1998, 338: 727-734.
  • 6Ekstrom P, Carling L, Wetterhus S, Wingren PE, Anker-Hansen O, Lundegardh G, Thorhallsson, E, Unge P,Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Stand J Gastroenterol, 1996, 31: 753-758.
  • 7Stupnicki T, Dietrich K, Gonzalez-Carro P, Straszak A,Terjung A, Thomas KB, Luhmann R, Fischer R, Efficacy and tolerability of pantoprazole compared with misoprostol tor the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion, 2003, 68: 198-208.
  • 8Muller P, Simon B. The action of the proton pump inhibitor pantoprazol against acetylsalicylie acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison.Arzneimittelforschung, 1998, 48: 482-485.
  • 9Bianchi Porro G, Lazzaroni M, Imbesi V, Montrone F,Santagada T. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal antiinflammatory drugs: a prospective, placebo-controlled,double-blind, parallel-group study. Dig Liver Dis, 2000,32: 201-208.
  • 10Goldstein JL, Huang B, Amer F, Christopoulos NG. Ulcer recurrence in high-risk patients receiving nonsteroidal anti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis. Clin Ther, 2004, 26: 1637-1643.

共引文献13

同被引文献112

引证文献17

二级引证文献151

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部